TEL: 044-952-0102


Pharmacogenomics Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 704967
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
本日の銀行送金レート: 1USD=108.30円で換算しております。
世界のゲノム薬理学(PGx)市場:技術(DNAシーケンシング、マイクロアレイ、ポリメラーゼ連鎖反応、電気泳動、質量分析)、用途、地域別 Pharmacogenomics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 115 Pages




第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場のダイナミクス

  • 成長要因
    • 精密医療への注目
    • 研究開発における支出の増加
    • 薬物有害反応の発生率の高さ
    • 安全性および有効性の向上による医薬品開発研究の成功率の上昇
  • 阻害要因
    • 薬物応答に影響を与える遺伝子変異の検出の難しさ
    • 償還制度の問題
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 技術別
    • DNAシーケンシング
    • マイクロアレイ
    • ポリメラーゼ連鎖反応
    • 電気泳動
    • 質量分析
    • その他
  • 用途別
    • 創薬
    • 個別化治療
    • 腫瘍
    • 疼痛管理
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 企業プロファイルと競合情勢

  • Abbott Laboratories, Inc.
  • Affymetrix, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.

第9章 市場の将来展望

Product Code: 62781

Market Overview

The propelling factors for the growth of the pharmacogenomics market include the increased expenditure in R&D and an increase in the rate of adverse reactions, which has led to the higher adoption of pharmacogenomics in the global market. The increasing focus on precision medicine, along with the need to enhance drug safety and efficacy, is also further fuelling the growth of this market.

The increasing focus on precision medicine is expected to augment the pharmacogenomics market, as the goal of the precision medicine approach is to integrate genetic and environmental information of particular diseases and/or their responses to particular treatments. This is done to determine or assist in targeted drug therapies, as well as in treatment procedures to be adopted to minimize the side effects and improve results, which will require pharmacogenomics extensively. For instance, in the United States, in 2015, the government announced a new precision medicine initiative to accelerate progress toward individualized care that takes genetic variability into account for various chronic disorders.

Pharmacogenomics is also helpful in cancer treatment and has proved to improve the survival of patients, and at the same time, has found to reduce the unnecessary cost due to unresponsive treatment by patients. Hence, pharmacogenomics for cancer therapy has led to a number of important discoveries in the current cancer treatment, hence, driving the market growth during the forecast period.

The increasing expenditure in R&D and an increase in the rate of adverse reactions have led to the higher adoption of pharmacogenomics in the global market. Furthermore, there is a rapid increase in the number of research studies related to sequencing, especially next-generation sequencing, which is expected to increase the demand for pharmacogenomic tests in the future.

Scope of the Report

As per the scope of this report, pharmacogenomics is defined as the branch of biotechnology where genomic information is used to study the effect of drugs on an individual, thus, providing accurate insights in making clinical decisions and further determining the most effective way of treatment by varying the dosages of drugs. The field of pharmacogenomics is predicted to treat a wide range of health problems, including cardiovascular diseases, Alzheimer'a disease, cancer, HIV/AIDS, and asthma, in the near future.

Key Market Trends

Drug Discovery is the Segment under Application that is Expected to Grow the Fastest during the Forecast Period

Pharmacogenomics is one of the major emerging trends in the field of medical science, which greatly influences the drug development process. With the use of pharmacogenomics, target identification by drugs has become relatively easy, which ensures much higher chances of success for the approval of drugs. In addition, out of 500 genes, only 50 disease genes have drug availability in the market today. This emphasizes the market opportunity in the future for different manufacturers to concentrate on drug discovery using pharmacogenomics.

Pharmacogenomics has also found applications in the treatment of cancer patients, by anticipating the possible differences in drug response, resistance, efficacy, and toxicity of the chemotherapeutic and targeted immune biologic agents. Therefore, pharmacogenomics for cancer therapy has led to a number of important discoveries in the current cancer treatment, which has helped in the growth of the oncology segment of the market studied.

North America holds the Largest Share of the Market and is Expected to Follow the Same Trend over the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period, due to the presence of high per capita healthcare expenditure, coupled with high patient awareness levels, and the high prevalence of target diseases. Moreover, the increasing preference for personalized treatment, along with its high adoption rate, is further contributing to the growth of the market.

Competitive Landscape

The large interest of researchers and investment in the safety and efficiency of drugs by companies are one the major factors responsible for the growth of the market. The government is also involved in funding companies that work to develop bioinformatics technology for precision medicine research applications.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Focus on Precision Medicine
    • 4.2.2 Increasing Expenditure in R&D
    • 4.2.3 High Rate of Adverse Drug Reaction
    • 4.2.4 Enhancement of Drug Safety and Efficiency to Increase Success Rates in Pharmaceutical R&D
  • 4.3 Market Restraints
    • 4.3.1 Difficulties in Detecting Gene Variation that Affect Drug Response
    • 4.3.2 Reimbursement Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Technology
    • 5.1.1 DNA Sequencing
    • 5.1.2 Microarray
    • 5.1.3 Polymerase Chain Reaction
    • 5.1.4 Electrophoresis
    • 5.1.5 Mass Spectrometry
    • 5.1.6 Other Technologies
  • 5.2 By Application
    • 5.2.1 Drug Discovery
    • 5.2.2 Neurology
    • 5.2.3 Oncology
    • 5.2.4 Pain Management
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories Inc.
    • 6.1.2 Biomerieux
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bayer AG
    • 6.1.5 Becton, Dickinson and Company
    • 6.1.6 Bio-Rad Laboratories Inc.
    • 6.1.7 F. Hoffmann-La Roche Ltd
    • 6.1.8 Illumina Inc.
    • 6.1.9 Qiagen
    • 6.1.10 Thermo Fisher Scientific Inc.